financetom
Business
financetom
/
Business
/
Brazilian gunmaker Taurus signs JV with Jindal Group
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Brazilian gunmaker Taurus signs JV with Jindal Group
Jan 27, 2020 7:43 AM

Brazilian gunmaker Taurus Armas SA has signed a joint venture with Indian steelmaker Jindal Group to produce guns in India, according to a securities filing on Monday.

Share Market Live

NSE

Under the agreement, Jindal will hold a 51 percent stake in the venture and Taurus the remaining shares. The deal was signed during Brazil’s President Jair Bolsonaro visit to India.

First Published:Jan 27, 2020 4:43 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical
BRIEF-Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical
Nov 4, 2025
Nov 4 (Reuters) - Evoke Pharma Inc ( EVOK ): * EVOKE PHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY QOL MEDICAL * EVOKE PHARMA INC ( EVOK ): PROPOSED DEAL FOR FOR $11.00 PER SHARE IN CASH AT CLOSING Source text: Further company coverage: ...
Wingstop Q3 system-wide sales rise 10%, helped by new restaurants
Wingstop Q3 system-wide sales rise 10%, helped by new restaurants
Nov 4, 2025
Overview * Wingstop ( WING ) fiscal Q3 system-wide sales rise 10% to $1.4 bln * Adjusted EBITDA for fiscal Q3 grows 18.6% to $63.7 mln, highest quarter on record * Company opened 114 net new restaurants, achieving 19.3% net new unit growth Outlook * Wingstop ( WING ) revises 2025 domestic same store sales growth to decline 3%-4% *...
Nuvectis Pharma Q3 net loss widens
Nuvectis Pharma Q3 net loss widens
Nov 4, 2025
Overview * Nuvectis Q3 net loss widens to $7.5 mln, driven by milestone and study costs * Cash position improves to $35.4 mln, supported by public offering and ATM facility * NXP900 Phase 1b program initiated, showcasing therapeutic potential in advanced cancers Outlook * Cash runway expected to support operations into 3Q-2027 Result Drivers * Research and development expenses were...
Hillman Q3 net sales rise 8%, beat estimates
Hillman Q3 net sales rise 8%, beat estimates
Nov 4, 2025
Overview * Hillman Q3 2025 net sales rise 8% to record $424.9 mln, beating analyst expectations * Adjusted EPS for Q3 2025 beats consensus, reaching $0.22 per share * Company repurchased 325.6 thousand shares, totaling $3.2 mln Outlook * Hillman maintains FY 2025 net sales guidance at $1.535 to $1.575 bln * Company raises FY 2025 adjusted EBITDA guidance to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved